Density dependence and evolvability limit adaptive therapy in non-small cell lung cancer mouse model
- 1Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center and Research Institute
Abstract
Using NSG mice grafted with H3122 non-small cell lung cancer cells, we compared outcomes from (1) continuous therapy with alectinib, (2) adaptive therapy where alectinib was cycled on and off based on a mouse’s tumor burden, and (3) no treatment. Adaptive therapy has proven successful in mouse models and clinical trials. The success of adaptive therapy improves when either there is density-dependent feedbacks favoring competition by sensitive over resistant cancer cells when therapy is off, or when the rate at which the population of cancer cells becomes more sensitive to therapy during periods of no treatment is faster than the rate at which resistance increases when on therapy. We found tumor growth rates were lowest under continuous therapy and highest under no therapy with adaptive therapy in between. We fitted the data to three separate game-theory models of resistance evolution where we let resistance be a quantitative trait consistent with resistance mechanisms to alectinib. All models successfully identified why adaptive therapy proved less successful than continuous: there was no evidence for favorable density-dependent feedbacks; and there was no significant difference in the rate of evolution towards or away from resistance when therapy was on or off.
Related
- Adaptive Functional Clustering with Structured Dependence via Variational Inference
- Scalable Variable Selection under Predictor Dependence with Adaptive Virtual Dummies
- Halve-Then-Greedy: Adaptive Sampling for Posterior Success with Near-Optimal Instance Dependence
- DOMIC: Provably Calibrated Detection of Dependence-Structure Change Points via Density-Operator Mutual Information
- Adaptive LASSO Penalized Minimum Density Power Divergence Estimation through Least Squares Approximation: Application to Bone Mineral Density Data from the SWAN Study
BibTeX
@article{pressley2026density,
title = {{Density dependence and evolvability limit adaptive therapy in non-small cell lung cancer mouse model}},
author = {Mariyah Pressley and Jessica J. Cunningham and Luiza Simoes and Robert A. Gatenby and Joel S. Brown and Stanislav Avdieiev},
journal = {Scientific Reports},
year = {2026},
month = aug,
doi = {10.1038/s41598-026-63987-x},
url = {https://doi.org/10.1038/s41598-026-63987-x},
note = {CC BY},
}
RIS
TY - JOUR
TI - Density dependence and evolvability limit adaptive therapy in non-small cell lung cancer mouse model
AU - Mariyah Pressley
AU - Jessica J. Cunningham
AU - Luiza Simoes
AU - Robert A. Gatenby
AU - Joel S. Brown
AU - Stanislav Avdieiev
PY - 2026
DA - 2026/08/01
JO - Scientific Reports
DO - 10.1038/s41598-026-63987-x
UR - https://doi.org/10.1038/s41598-026-63987-x
AB - Using NSG mice grafted with H3122 non-small cell lung cancer cells, we compared outcomes from (1) continuous therapy with alectinib, (2) adaptive therapy where alectinib was cycled on and off based on a mouse’s tumor burden, and (3) no treatment. Adaptive therapy has proven successful in mouse models and clinical trials. The success of adaptive therapy improves when either there is density-dependent feedbacks favoring competition by sensitive over resistant cancer cells when therapy is off, or when the rate at which the population of cancer cells becomes more sensitive to therapy during periods of no treatment is faster than the rate at which resistance increases when on therapy. We found tumor growth rates were lowest under continuous therapy and highest under no therapy with adaptive therapy in between. We fitted the data to three separate game-theory models of resistance evolution where we let resistance be a quantitative trait consistent with resistance mechanisms to alectinib. All models successfully identified why adaptive therapy proved less successful than continuous: there was no evidence for favorable density-dependent feedbacks; and there was no significant difference in the rate of evolution towards or away from resistance when therapy was on or off.
SN - 2045-2322
ER -